MRA Advisory Group Bets Big on Amgen as Earnings Surge

MRA Advisory Group has significantly increased its stake in Amgen Inc., purchasing an additional 3,454 shares in the second quarter, according to a recent disclosure with the Securities and Exchange Commission. This brings MRA's total holdings in Amgen to 4,256 shares, valued at $1,541,000.

This is not an isolated instance of increased interest in Amgen; several other institutional investors have also added to their stakes in the company during the same period. For example, Anfield Capital Management LLC grew its holdings by 1,000% and now owns 77 shares worth $25,000.

Amgen's recent quarterly earnings report exceeded expectations, with revenue of approximately $10.05 billion, up 9.5% year over year, and adjusted earnings of $6.29 per share surpassing the consensus estimate of $5.62. The company has also raised its full-year guidance to $22.30 to $23.50 per share.

Analysts' predictions for Amgen's future performance vary widely; while some, like BMO Capital Markets and TD Cowen, have set price targets of $450 and $452 respectively, others, such as Wells Fargo and Canaccord Genuity, are more cautious, predicting a lower value of $400 and $384.